EURETINA 2020 Virtual – Free Papers

Programme ScheduleProgramme Overview
EURETINA Sessions Keynotes Symposia Instructional Courses Free Paper Abstracts Poster Abstracts Prize Papers Load Favourites

Please note that all times are in Central European Summer Time (CEST)

Programme Filter
timer Loading ... please wait
Count: 88 Abstracts

Abstract Channel
Programme Breakdown
Count: 12 Abstracts

Abstract Channel
Programme Breakdown
Count: 12 Abstracts

Abstract Channel
Programme Breakdown
Count: 81 Abstracts

Abstract Channel
Programme Breakdown
Count: 13 Abstracts

Abstract Channel
Programme Breakdown
Count: 55 Abstracts

Abstract Channel
Programme Breakdown
Count: 21 Abstracts

Abstract Channel
Programme Breakdown
Count: 35 Abstracts

Abstract Channel
Programme Breakdown
Count: 25 Abstracts

Abstract Channel
Programme Breakdown
Count: 104 Abstracts

Abstract Channel
Programme Breakdown
Count: 109 Abstracts

Abstract Channel
Programme Breakdown
close
timer Loading ... please wait

EURETINA 2020 Virtual

Frank Holz

Prof. Frank G. Holz, FEBO, FARVO

University Eye Hospital Bonn
EURETINA President

Dear Colleagues,

We are delighted to announce EURETINA 2020 Virtual, taking place from 2-4 October, and delivering the highest quality scientific content curated by world-renowned experts in the field of retina.

The Virtual Congress will present up to 4 Channels of scientific content, to include EURETINA Sessions & Keynotes on Channel 1, International Symposia on Channel 2, Instructional Courses on Channel 3, as well as a fourth Channel running on Saturday to present the highest scoring Free Papers.

Having extensively researched the most favourable and engaging formats for this new digital landscape, session times have been reduced to 45 minutes, to present engaging, shortened presentations with live discussion throughout.

The virtual Congress will also present a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and are glad to be able to still have the opportunity to engage directly with them during the annual meeting.

We very much hope that you will join us at this year’s first virtual EURETINA Congress and encourage you to avail of the reduced registration rates until September 25th.

With very best wishes,

Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA

Registration Information

Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.

If you are an EURETINA Member or have submitted an abstract, you may already have an account.

If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.

Prices are in Euro & listed without VAT
VAT is charged at 20%
EARLY FEE
5 Aug – 25 Sept
LATE FEE
26 Sept – 4 Oct
EURETINA Member 50 65
Non – Member 95 110
Ophthalmic Nurse / Technician* 50 65

*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.

Additional Info Categories Groups Cancellations

Keynote Lectures – EURETINA 2020 Virtual

Richard Spaide USA speakerfeature EURETINA Lecture Richard Spaide USA
Marta S. FigueroaKreissig LectureMarta S. FigueroaSPAIN
Stanislao RizzoGisbert Richard Lecture Stanislao RizzoITALY

src

Safety Review Committee (SRC) Report

Post-marketing reports have highlighted the occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion with brolucizumab, which differs from the common experience with other approved anti-VEGF agents.

A Safety Review Committee (SRC) consisting of clinical trial, imaging, and uveitis experts as well as Data Monitoring Committee members was established by Novartis to independently review these post-marketing cases.

View Report

Sign up to EURETINA


© EURETINA All rights reserved
Loading please wait